5 completed, 1 recruiting. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 2 |
Follow Transformed Follicular Lymphoma: new trials by email Literature Review of Transformed Follicular Lymphoma trials Research Report on Transformed Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 16 | 2021-01-21 | 2026-04-08 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 18 | 2020-08-14 | 2024-08-20 |
| Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma CD19 CAR-T Expressing IL7 and CCL19 - Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 39 | 2018-09-22 | 2025-07-16 | |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Tazemetostat, Prednisolone - B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1) | Phase 1 / Phase 2 | Completed | Epizyme, Inc. | 400 | 2013-06-13 | 2024-03-26 |
| MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine Alisertib (MLN8237), Rituximab, Vincristine - Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 45 | 2011-08-09 | 2018-03-27 |
Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Follicular (4) · Lymphoma, Mantle-Cell (4) · Burkitt Lymphoma (3) · Lymphoma, B-Cell (3) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Neoplasms (2) · Waldenstrom Macroglobulinemia (2) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Peripheral (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoproliferative Disorders (6) · Neoplasms by Histologic Type (6) · Lymphoma, Non-Hodgkin (5) · Neoplasms (4) · DNA Virus Infections (3) · Epstein-Barr Virus Infections (3) · Herpesviridae Infections (3) · Infections (3) · Lymphoma, B-Cell (3) · Tumor Virus Infections (3)
MLN 8237 (1) · Methylprednisolone (1) · Prednisolone (1) · Rituximab (1) · Vincristine (1) · prednisolone acetate (1) · prednisolone phosphate (1) · tazemetostat (1)
Calibr, a division of Scripps Research (2) · Epizyme, Inc. (1) · Millennium Pharmaceuticals, Inc. (1) · Natera, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
United States (5) · Italy (2) · United Kingdom (2) · Australia (1) · Canada (1) · China (1) · France (1) · Germany (1) · Poland (1) · Spain (1) · Taiwan (1) · Ukraine (1)
PMID 29650362, PMID 30082475, PMID 33035457, PMID 34515338, PMID 37981564, PMID 39563886